Amphastar Pharmaceuticals (AMPH): Price-to-Projected Revenue Ratio
The forward P/S ratio reflects the market valuation of future revenues for Amphastar Pharmaceuticals (AMPH), with the latest value recorded as 1.20. Stringent FDA requirements and patent protection for delivery systems create significant barriers to entry. Current growth is supported by sales of nasal glucagon and injectable analogs, while operational efficiency is enhanced by leveraging external partners for clinical trials and packaging.
Metric breakdowns and analytics for Amphastar Corp (AMPH)
- current price and projected stock value:
- stock exchange capitalization data:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital Amphastar Pharmaceuticals|AMPH - Long-Term Debt to Capital|Short-Term Debt to Equity Amphastar Pharmaceuticals|AMPH - Company Total Debt Obligations|Debt to Book Value Amphastar Corp|AMPH - Amount of Long-Term Liabilities|Company Short-Term Debts Amphastar Pharmaceuticals|Quick Liquidity amphastar.com
- business earnings and investment ratios data:
AMPH - Final Profit|Future Profit Amphastar Pharmaceuticals|AMPH - Company Value to Net Income|Future Price to Earnings Amphastar|AMPH - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Amphastar Corp|AMPH - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Amphastar Pharmaceuticals|AMPH - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months amphastar.com|AMPH - Earnings per share increase in current year|Net earnings per share growth forecast for next year Amphastar Pharmaceuticals
- sales volume and revenue information:
Comprehensive company analysis:Amphastar Pharmaceuticals, Inc. (AMPH)
The complexity of producing inhalation generics and stringent FDA oversight create sustainable competitive advantages for Amphastar Pharmaceuticals (AMPH). By analyzing the forward P/S ratio, an investor assesses current market capitalization relative to projected revenue for the coming year. This metric helps smooth out reporting gaps by measuring market expectations regarding business growth rates. Elevated indicator values signal that the asset is overbought and increase the risk of a price correction.
Competing companies
Forward P/S Multiple HLN (Haleon)|Forward P/S Multiple Kenvue Inc KVUE|VRNA - Price-to-Projected Revenue Ratio|Jyong Bio (MENS) - Forward Price-to-Revenue Multiple|Ligand Pharmaceuticals (LGND) - Price-to-Projected Revenue Ratio|Future Price to Revenue AMRX (amneal.com)|PRGO (Perrigo) - Forward P/S Multiple|ALVO: Forward Price to Sales|Forward P/S Multiple LQDA|Forward P/S Multiple Galapagos Corp (GLPG)|Price-to-Projected Revenue Ratio ANI Pharmaceuticals ANIP|Market Cap to Expected Sales Ratio mannkindcorp.com (MNKD)|PCRX: Forward Price-to-Revenue Multiple|ARS Pharmaceuticals Inc - Price to Expected Revenue Ratio|TBPH: Forward P/S Multiple|Aquestive Corp (AQST) - Forward P/S Multiple|Price-to-Projected Revenue Ratio scPharmaceuticals, Inc.|TECX: Forward Price to Sales|Forward Price-to-Revenue Multiple TNXP (Tonix Pharmaceuticals Holding Corp.)|SXTC (sxtchina.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Eupraxia Pharmaceuticals Inc. EPRX|BHST (BioHarvest Sciences Inc) - Future Price to Revenue|eXoZymes Inc - Forward P/S Multiple|Forward Price to Sales ORMP (Oramed Pharmaceuticals)|ENTX: Forward P/S Multiple|MindWalk Holdings, Inc. (HYFT) - Forward P/S Multiple|Price-to-Projected Revenue Ratio ABVC BioPharma Inc|CPIX: Forward Price to Sales|Price-to-Projected Revenue Ratio Quantum BioPharma Ltd (QNTM)|Forward Price-to-Revenue Multiple fibrogen.com FGEN|Forward P/S Multiple TELO (Telomir Pharmaceuticals, Inc.)|Forward P/S Multiple Rani Therapeutics Holdings RANI|Synergy CHC Corporation - Forward P/S Multiple|Rallybio Corporation (RLYB) - Forward Price-to-Revenue Multiple|LEXX: Forward P/S Multiple|Market Cap to Future Revenue Ratio pulmatrix.com (PULM)|Forward Price-to-Revenue Multiple PTHL|Forward P/S Multiple Aptorum|Forward Price-to-Revenue Multiple LYRA (Lyra Therapeutics, Inc)|Price to Expected Revenue Ratio IBO|Forward P/S Multiple TNFA (TNF Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio cbdMD Inc. (YCBD)|PainReform - Forward P/S Multiple|Altamira Therapeutics (CYTO) - Forward Price-to-Revenue Multiple|LIPO: Forward P/S Multiple|OptiNose Corp (OPTN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals|Price-to-Projected Revenue Ratio PROC|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Market Cap to Expected Sales Ratio Qilian International Holding Group|Forward P/S Multiple SLRN (ACELYRIN, Inc.)|Forward P/S Multiple TFF Pharmaceuticals, Inc TFFP
